Text message workouts could ease strain on hearts of PAH patients
NCT ID NCT06477640
First seen Jun 26, 2026 · Last updated Jul 16, 2026 · Updated 2 times
Summary
This study tests whether a home rehabilitation program using daily text or email messages with simple exercises can reduce the number of heartbeats needed during a 6-minute walk in people with pulmonary arterial hypertension (PAH). Researchers will enroll 55 adults with PAH and compare those who get exercise messages to those who get neutral messages. The goal is to see if this low-cost approach can improve heart efficiency and quality of life.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- daily exercise messages via text or email
- What this could lead to
- If it works, this could offer a simple, low-cost way to help people with PAH manage their condition at home and feel better day-to-day.
- What could go wrong
- This is a small, early-stage study with only 55 participants, so results may not apply to everyone. The exercise program is gentle and low-risk, but it may not provide clear benefits.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 55 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jul 2024
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Follows at University of Rochester Medical Center Pulmonary Hypertension Clinic. * Adult patients (\>18 years old) with right heart catheterization confirmed pulmonary hypertension (PAH) on stable vasodilator dosing for at least 30 days. No planned titrations will occur during the 12-week study. If during the study, the treating physician feels it is necessary for safety reasons to adjust dosing, the subject will remain in their assigned group. * Access to a smart phone or email to receive daily messages. If patients do not have access to either, we will offer a smartphone with cellular service for use during the study to receive daily messages. * Clinically stable by the investigator (i.e., we will not enroll patients who endorse ongoing improvement or clinical worsening at enrollment). * The treating investigator (Dr. Lachant or Dr. White) will review the clinical data of an eligible patient and establish them as safe to participate prior to approaching the patient for enrollment (i.e. not in decompensated heart failure or with recurrent pre-syncopal episodes prior to enrollment). Exclusion Criteria: * Pregnancy. * Pulmonary Hypertension Groups 2-5. * Resting tachycardia \>120 beats/m during screening. * Inability to walk. * WHO Functional Class IV * Lack of access to email or text messaging. * Inability to follow daily instructions. including the two home 6-minute walk tests during the initial monitoring period. This is to show compliance with the protocol. * Participating in a self-reported rehabilitation or exercise program. * Oxygen therapy of more than 6 L/min at rest. * Principal Investigator discretion
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Pulmonary arterial hypertension (PAH) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Rochester Medical Center
Rochester, New York, 14642, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a week at sea level ease the strain of High-Altitude lung disease?
- Can a week at sea level ease the strain of High-Altitude heart disease?
- Can a week at sea level ease strain on High-Altitude hearts?
- Can a week at sea level ease strain on the Heart's blood vessels?
- Can a week at sea level ease the strain of High-Altitude living on the heart?
- Can a week at sea level ease sleep and oxygen strain for High-Altitude heart patients?